NO984035L - Farmas°ytiske formuleringer med forlenget frigivelse inneholdende mizolastin - Google Patents

Farmas°ytiske formuleringer med forlenget frigivelse inneholdende mizolastin

Info

Publication number
NO984035L
NO984035L NO984035A NO984035A NO984035L NO 984035 L NO984035 L NO 984035L NO 984035 A NO984035 A NO 984035A NO 984035 A NO984035 A NO 984035A NO 984035 L NO984035 L NO 984035L
Authority
NO
Norway
Prior art keywords
pharmaceutical formulations
extended release
formulations containing
release pharmaceutical
mizolastine
Prior art date
Application number
NO984035A
Other languages
English (en)
Other versions
NO315841B1 (no
NO984035D0 (no
Inventor
Maryvonne Chariot
Gareth Lewis
Jean Montel
Original Assignee
Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo filed Critical Synthelabo
Publication of NO984035D0 publication Critical patent/NO984035D0/no
Publication of NO984035L publication Critical patent/NO984035L/no
Publication of NO315841B1 publication Critical patent/NO315841B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO19984035A 1996-03-04 1998-09-02 Farmasöytiske formuleringer med forlenget frigivelse inneholdende mizolastin NO315841B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9602662A FR2745500B1 (fr) 1996-03-04 1996-03-04 Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
PCT/FR1997/000355 WO1997032584A1 (fr) 1996-03-04 1997-02-28 Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine

Publications (3)

Publication Number Publication Date
NO984035D0 NO984035D0 (no) 1998-09-02
NO984035L true NO984035L (no) 1998-10-22
NO315841B1 NO315841B1 (no) 2003-11-03

Family

ID=9489799

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19984035A NO315841B1 (no) 1996-03-04 1998-09-02 Farmasöytiske formuleringer med forlenget frigivelse inneholdende mizolastin

Country Status (35)

Country Link
US (2) US6165507A (no)
EP (1) EP0906101B1 (no)
JP (2) JP2000512617A (no)
KR (1) KR100369888B1 (no)
CN (1) CN1112929C (no)
AR (1) AR006082A1 (no)
AT (1) ATE219365T1 (no)
AU (1) AU725494B2 (no)
BG (1) BG63451B1 (no)
BR (1) BR9707827A (no)
CA (1) CA2247405C (no)
CO (1) CO4780020A1 (no)
CY (1) CY2293B1 (no)
CZ (1) CZ291418B6 (no)
DE (1) DE69713505T2 (no)
DK (1) DK0906101T3 (no)
EE (1) EE03511B1 (no)
ES (1) ES2177942T3 (no)
FR (1) FR2745500B1 (no)
HK (1) HK1017999A1 (no)
HU (1) HU227472B1 (no)
IL (1) IL126050A (no)
IN (1) IN187739B (no)
NO (1) NO315841B1 (no)
NZ (1) NZ331947A (no)
OA (1) OA10854A (no)
PL (1) PL189813B1 (no)
PT (1) PT906101E (no)
RU (1) RU2173997C2 (no)
SK (1) SK282112B6 (no)
TR (1) TR199801574T2 (no)
TW (1) TW491711B (no)
UA (1) UA49004C2 (no)
WO (1) WO1997032584A1 (no)
ZA (1) ZA971830B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002087960A (ja) * 2000-07-14 2002-03-27 Toyama Chem Co Ltd 徐放性錠剤
DK1322158T3 (da) * 2000-10-02 2012-11-19 Usv Ltd Farmaceutiske præparater med langvarig frigivelse, som indeholder metformin, og fremgangsmåde til fremstilling deraf
US7052706B2 (en) 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
NZ542176A (en) * 2003-03-04 2007-12-21 Nostrum Pharmaceuticals Inc Control release formulation containing a hydrophobic material as the sustained release agent
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
EP2564833B1 (en) 2008-07-28 2017-12-20 Takeda Pharmaceutical Company Limited Photostabilized pharmaceutical composition
JP5744412B2 (ja) * 2010-03-26 2015-07-08 テバ製薬株式会社 フロセミド製剤
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364945A (en) * 1979-12-13 1982-12-21 Whittle Barry J Nasal composition for relieving nasal distress
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
FR2587029B1 (fr) * 1985-09-11 1987-10-30 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
JPH0776172B2 (ja) * 1986-04-16 1995-08-16 藤沢薬品工業株式会社 マトリツクス錠
JPS62283926A (ja) * 1986-06-02 1987-12-09 Nippon Chemiphar Co Ltd 塩酸ニカルジピン持続性組成物
DE3812799A1 (de) * 1988-04-16 1989-10-26 Sanol Arznei Schwarz Gmbh Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung
JP3195391B2 (ja) * 1991-11-14 2001-08-06 エスエス製薬株式会社 徐放性トラピジル錠
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤

Also Published As

Publication number Publication date
HUP9902458A2 (hu) 2000-05-28
ZA971830B (en) 1997-09-04
NO315841B1 (no) 2003-11-03
SK121098A3 (en) 1999-01-11
JP2007182451A (ja) 2007-07-19
NO984035D0 (no) 1998-09-02
TR199801574T2 (xx) 1998-11-23
IL126050A0 (en) 1999-05-09
PL328763A1 (en) 1999-02-15
ATE219365T1 (de) 2002-07-15
FR2745500A1 (fr) 1997-09-05
CA2247405A1 (en) 1997-09-12
KR100369888B1 (ko) 2003-05-17
BG102692A (en) 1999-04-30
EP0906101A1 (fr) 1999-04-07
EP0906101B1 (fr) 2002-06-19
DE69713505D1 (de) 2002-07-25
HUP9902458A3 (en) 2002-11-28
CO4780020A1 (es) 1999-05-26
WO1997032584A1 (fr) 1997-09-12
CN1112929C (zh) 2003-07-02
BG63451B1 (bg) 2002-02-28
RU2173997C2 (ru) 2001-09-27
CY2293B1 (en) 2003-07-04
HK1017999A1 (en) 1999-12-10
PT906101E (pt) 2002-09-30
HU227472B1 (en) 2011-07-28
DE69713505T2 (de) 2003-02-13
EE9800275A (et) 1999-02-15
PL189813B1 (pl) 2005-09-30
CZ279198A3 (cs) 1999-01-13
BR9707827A (pt) 1999-07-27
CA2247405C (en) 2004-04-20
US20050202089A1 (en) 2005-09-15
NZ331947A (en) 2000-03-27
OA10854A (fr) 2003-02-05
TW491711B (en) 2002-06-21
FR2745500B1 (fr) 1998-04-03
IN187739B (no) 2002-06-15
IL126050A (en) 2004-05-12
ES2177942T3 (es) 2002-12-16
UA49004C2 (uk) 2002-09-16
US6165507A (en) 2000-12-26
AU1930097A (en) 1997-09-22
JP2000512617A (ja) 2000-09-26
CN1212624A (zh) 1999-03-31
SK282112B6 (sk) 2001-11-06
EE03511B1 (et) 2001-10-15
AR006082A1 (es) 1999-08-11
DK0906101T3 (da) 2002-10-14
AU725494B2 (en) 2000-10-12
KR19990087387A (ko) 1999-12-27
CZ291418B6 (cs) 2003-03-12

Similar Documents

Publication Publication Date Title
DK0973527T3 (da) Clarithromycinformuleringer med forlænget frigivelse
NO992339D0 (no) Farmas°ytiske formuleringer
DK1001813T3 (da) Farmaceutiske formuleringer indeholdende voriconazol
NO942477D0 (no) Opioide formuleringer med forlenget, regulert frigivelse
FI944712A (fi) Suun kautta annettavia opioidisia kestovaikutteisia formulaatioita
EE200000383A (et) Peroraalne farmatseutiline pikendatud vabanemisega annusvorm
DE59712959D1 (de) Orale pharmazeutische zubereitung enthaltend ibandronat
ID18352A (id) Komposisi-komposisi farmasi
NO20002126L (no) Formulering med forlenget frigjøring
NO20015670L (no) Forbedrede farmasöytiske formuleringer
PT868911E (pt) Formulacoes de rapamicina para administracao oral
ID16781A (id) Formulasi-formulasi farmasi
NO984035L (no) Farmas°ytiske formuleringer med forlenget frigivelse inneholdende mizolastin
NO996044L (no) Rapamycinformuleringer for oral administrasjon
EE9900206A (et) N-sulfonüülindoliiniderivaate sisaldavad farmatseutilised kompositsioonid
ITMI941169A0 (it) Formulazioni farmaceutiche
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
PT941100E (pt) Composicoes farmaceuticas
EP1173216A4 (en) PHARMACEUTICAL FORMULATIONS
ITMI962628A0 (it) Composizione farmaceutica
DE69706833D1 (de) Pharmazeutische zusammensetzungen enthaltend famciclovir monohydrat
GB9906126D0 (en) Pharmaceutical formulations
SE9601854D0 (sv) Farmaceutisk komposition
SE9604299D0 (sv) Pharmaceutical composition
ID17133A (id) Komposisi farmasi

Legal Events

Date Code Title Description
MK1K Patent expired